Perrigo (PRGO) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sarepta Therapeutics (SRPT) has outperformed Perrigo (PRGO) over the past year, losing 22.1% versus a loss of 33.0%. Over five years, PRGO leads with a -67.6% price change compared with -78.4% for SRPT. Perrigo is the larger company by market cap ($2.09 billion vs $1.89 billion), about 1.1 times the size, while Sarepta Therapeutics is growing revenue faster (+15.6% vs -2.8%).
On valuation, Perrigo trades at a lower forward P/E (6.3x vs 7.4x for Sarepta Therapeutics). Perrigo pays a dividend yielding 7.69%, while Sarepta Therapeutics does not currently pay one. Sarepta Therapeutics converts more of its revenue into profit, with a net margin of -32.5% versus -33.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRGO | SRPT |
|---|---|---|
| Share price | $15.08 | $17.89 |
| Market cap | $2.09B | $1.89B |
| 1-day change | +4.00% | -1.76% |
| YTD return | +4.17% | -15.38% |
| 1-year return | -33.03% | -22.11% |
| 5-year return | -67.58% | -78.37% |
| Forward P/E | 6.29 | 7.42 |
| EPS (TTM) | $-12.28 | $-1.57 |
| Dividend yield | 7.69% | 0.00% |
| Annual dividend | $1.16 | $0.00 |
| Revenue (latest FY) | $4.25B | $2.20B |
| Revenue growth (YoY) | -2.75% | +15.58% |
| Net income (latest FY) | $-1.43B | $-713.41M |
| Gross margin | 35.14% | 98.84% |
| Operating margin | -26.39% | -31.83% |
| Net margin | -33.51% | -32.45% |
| 52-week high | $22.02 | $24.68 |
| 52-week low | $9.23 | $14.68 |
| Distance from 52-week high | -31.52% | -27.51% |
| Analyst consensus | none | hold |
| Avg. price target upside | +9.42% | +21.46% |
| Average volume | 2.80M | 2.99M |
| Shares outstanding | 138.37M | 105.63M |
| Employees | 8,100 | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRPT has outperformed PRGO by 10.9 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (7.69% vs 0.00%).
- Sarepta Therapeutics grew revenue faster in its latest fiscal year (+15.58% vs -2.75%).
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
PRGO vs SRPT FAQ
Which is bigger, Perrigo or Sarepta Therapeutics?
Perrigo (PRGO) is larger, with a market capitalization of $2.09B compared with $1.89B for Sarepta Therapeutics (SRPT).
Which stock has performed better over the past year, PRGO or SRPT?
SRPT returned -22.11% over the past 12 months, compared with -33.03% for PRGO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Perrigo or Sarepta Therapeutics?
Perrigo pays a dividend yielding 7.69%, while Sarepta Therapeutics does not currently pay a regular dividend.
Are Perrigo and Sarepta Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.